Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.58 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | CASR | P41180 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11587666 | 0.85 | ALOX5 (0.65) | HPGDCYP1A2CYP2C9CYP2C19HIF1A | |
| SCHEMBL3060259 | 0.85 | ALOX5 (0.57) | HPGDCYP1A2CYP2C9CYP2C19HIF1A | |
| SCHEMBL11697365 | 0.83 | HPGD (0.60) | HPGDCYP1A2CYP2C9CYP2C19HIF1A | |
| SCHEMBL718297 | 0.83 | HPGD (0.57) | HPGDCYP1A2CYP2C9CYP2C19HIF1A | |
| SCHEMBL11165753 | 0.83 | ALOX5 (0.62) | HPGDCYP1A2CYP2C9CYP2C19HIF1A | |
| SCHEMBL3962528 | 0.83 | RAB9A (0.56) | HPGDCYP1A2CYP2C9CYP2C19HIF1A | |
| SCHEMBL11173254 | 0.81 | ALOX5 (0.57) | HPGDCYP1A2CYP2C9CYP2C19HIF1A | |
| SCHEMBL5536307 | 0.81 | HPGD (0.66) | HPGDCYP1A2CYP2C9CYP2C19HIF1A | |
| SCHEMBL5159135 | 0.80 | HPGD (0.60) | HPGDCYP1A2CYP2C9CYP2C19HIF1A | |
| SCHEMBL11191161 | 0.80 | HPGD (0.60) | HPGDCYP1A2CYP2C9CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081937-A2 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20080287434-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | SANOFI-AVENTIS (FR) | 2008-11-20 | — | — | US | disclosed |
| EP-1931620-A1 | AMINO-ALKYL-AMIDE DERIVATIVES AS CCR3 RECEPTOR LIQUIDS | Sanofi-Aventis (FR) | 2008-06-18 | — | — | EP | disclosed |
| WO-2008051805-A2 | TRIAZOLO-PYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007034252-A1 | AMINO-ALKYL-AMIDE DERIVATIVES AS CCR3 RECEPTOR LIQUIDS | SANOFI-AVENTIS (FR) | 2007-03-29 | — | — | WO | disclosed |
| EP-0068563-A2 | Heterocyclic acetic acid compounds and compositions for treating bone diseases | THE PROCTER & GAMBLE COMPANY (US) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287434-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | CCR3, CCR1, CCR4 | HPGD 3574/4885CYP1A2 2460/4885CYP2C9 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.